News Releases

ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation New Drug Application (NDA) Submission Expected in Fourth Quarter of 2019 DEER PARK, Ill. --(BUSINESS WIRE)--Aug. 19, 2019-- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company

ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 ET-105 Acquisition Closed & Application Assigned PDUFA Date of March 17, 2020 Company to Host Conference Call and Webcast Today at 4:30p.m. ET ( 3:30 p.m. CT ) DEER PARK, Ill. , Aug.

-ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020 DEER PARK, Ill. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today

DEER PARK, Ill. , July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2019 financial and operating results on Tuesday,

DEER PARK, Ill. , July 12, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U. S Food and Drug Administration ( FDA ) provided Eton’s partner with a

Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019 ; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually DEER PARK, Ill.

DEER PARK, Ill. , May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will present at the 20 th Annual B.

– Four Products Currently Under Review with the FDA –  – Expecting Multiple Product Launches in Second Half of 2019 – – Company to Host Conference Call and Webcast today at 4:30 p.m. ET ( 3:30 p.m. CT ) - DEER PARK, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc.

DEER PARK, Ill. , April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2019 financial and operating results on Tuesday,

NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019 DEER PARK, Ill. , March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported